Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
in vivo
Biotech
BMS inks $1.5B deal to pull Orbital into its sphere of influence
Pushing deeper into in vivo cell therapies, BMS has struck a deal to buy Orbital and its pipeline led by a preclinical CD19 autoimmune program.
Nick Paul Taylor
Oct 10, 2025 8:45am
ARPA-H goes all in on in vivo cell therapy
Oct 8, 2025 4:04pm
Biotech shares first data for in vivo CAR-T that attracted AZ
Jul 7, 2025 2:27pm
Gene editor shelves sole clinical asset, lays off 25% of staff
May 19, 2025 2:28pm
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
May 7, 2025 10:00am
Novartis taps Vyriad’s viral vectors for in vivo T cell editing
Nov 20, 2024 12:00pm
